Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000031.xml
Klin Monbl Augenheilkd 2009; 226(5): 388-395
DOI: 10.1055/s-0028-1109432
DOI: 10.1055/s-0028-1109432
Statement
© Georg Thieme Verlag KG Stuttgart · New York
Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration – Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands e. V.
New Aspects in the Management of Exudative Age-Related Macular Degeneration – Current Position of the Retinological Society, the German Ophthalmology Society and the Professional Union of Ophthalmologists in GermanyFurther Information
Publication History
Eingegangen: 25.3.2009
Angenommen: 30.3.2009
Publication Date:
08 June 2009 (online)
![](https://www.thieme-connect.de/media/klimo/200905/lookinside/thumbnails/10.1055-s-0028-1109432-1.jpg)
Abstract
The socioeconomic strategy and some scientific aspects in the management of exudative age related macular degeneration (AMD) have changed since the last publication on preferred practice pattern [1] [2]. Furthermore new drugs are tested in clinical trials. Consequently it seems reasonable to re-evaluate the redommendations for the treatment of exudative AMD.
Schlüsselwörter
altersbedingte Makuladegeneration - Behandlungsrichtlinien
Key words
age related macular degeneration - preferred practice pattern
Literatur
- 1 Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd. 2007; 224 559-566
- 2 Aktuelle therapeutische Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe. 2007; 104 628-634
- 3 Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd. 2006; 223 271-278
- 4 Antoszyk A N, Tuomi L, Chung C Y. et al . Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008; 145 862-874
- 5 Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol. 2008; 92 1628-1635
- 6 Singerman L J, Masonson H, Patel M. et al . Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008; 92 1606-1611
- 7 Gragoudas E S, Adamis A P, Cunningham E T. et al . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351 2805-2816
- 8 Chakravarthy Jr U, Adamis A P, Cunningham E T. et al . Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006; 113 1508-1521
- 9 Farah S E. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed. Ophthalmic Surg Lasers Imaging. 2008; 39 294-298
- 10 Hughes M S, Sang D N. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2006; 37 446-454
- 11 Brown D M, Kaiser P K, Michels Jr M. et al . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355 1432-1444
- 12 Rosenfeld P J, Brown D M, Heier J S. et al . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355 1419-1431
- 13 Fachinformation Lucentis® (Stand August 2008). Rote Liste GmbH Novartis Pharma GmbH 2008
- 14 Regillo C D, Brown D M, Abraham P. et al . Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145 239-248
- 15 Lommatzsch A P, Heimes B, Gutfleisch M. et al . Die Therapie der vaskularisierten serosen Pigmentepithelabhebung bei AMD – Beobachtungen nach Wechsel des intravitrealen Medikamentes bei Therapieversagen. Klin Monatsbl Augenheilkd. 2008; 225 874-879
- 16 Alexander S L, Linde-Zwirble W T, Werther W. et al . Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology. 2007; 114 2174-2178
- 17 Dafer R M, Schneck M, Friberg T R. et al . Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol. 2007; 22 201-204
- 18 Investigator Notification for ranibizumab: Lucentis Meta-Analysis. Novartis NSO Basel CH 2008
- 19 Rote-Hand-Brief: Avastin – Bevacizumab. Roche Pharma AG. 2009; , http://www.pei.de/SharedDocs/Downloads/fachkreise/rhb/ 09 – 02 – 11-rhb-avastin,templateId = raw,property = publicationFile.pdf/ 09 – 02 – 11-rhb-avastin.pdf
- 20 Wild C, Adlbrecht C. Avastin® bei Altersbedingter Makuladegeneration. Analyse der Sicherheit und Nebenwirkungen. 2007; , http://eprints.hta.lbg.ac.at/ 718 / 1 /Rapid_Assessment_002.pdf
- 21 Schouten J S, La Heij E C, Webers C A. et al . A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009; 247 1-11
- 22 Ip M S, Scott I U, Brown G C. et al . Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008; 115 1837-1846
- 23 Gamulescu M A, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol. 2007; 245 1037-1040
- 24 Kook D, Wolf A, Neubauer A S. et al . Retinale Pigmentepithelrisse nach intravitrealem Bevacizumab bei AMD. Häufigkeit und Verlauf. Ophthalmologe. 2008; 105 158-164
- 25 Weinberger A W, Thiel M, Mohammadi B. et al . Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol. 2007; 144 294-296
- 26 Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). , http://www.med.upenn.edu/cpob/studies/CATT.shtml
- 27 Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA). , http://www.clinicaltrials.gov/ct2 /show/NCT00559715
- 28 Prävention des Sehverlustes bei Patienten mit altersabhängiger Makuladegeneration durch intravitreale Injektion von Bevacizumab und Ranibizumab. , http://www.pharmakologie-bremen.de/index.php/klinische-forschung/vibera
- 29 A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation. , http://www.controlled-trials.com/ISRCTN92166560
- 30 Fintak D R, Shah G K, Blinder K J. et al . Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008; 28 1395-1399
- 31 Angulo Bocco M C, Glacet-Bernard A, Zourdani A. et al . Injection intravitréenne: évaluation rétrospective de la technique et des complications d’une serie de 2028 injections. J Fr Ophtalmol. 2008; 31 693-698
- 32 Wu L, Martinez-Castellanos M A, Quiroz-Mercado H. et al . Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008; 246 81-87
- 33 Chappelow A V, Kaiser P K. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008; 68 1029-1036
- 34 Nguyen Q D, Shah S M, Hafiz G. et al . A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006; 113 1522 e1521-1522 e1514
- 35 VEGF Trap-Eye in Wet AMD CLEAR-IT 2: Summary of One-Year Key Results. 2008; , http://library.corporate-ir.net/library/ 11 / 119 / 119 576 /items/ 309 061 /Final2_0508_Week52_Website_Slides_9 – 26 – 08.pdf
- 36 Kleinman M E, Yamada K, Takeda A. et al . Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452 591-597
- 37 Dejneka N S, Wan S, Bond O S. et al . Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008; 14 997-1005
- 38 OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD. 2008; http://investor.opko.com/releasedetail.cfm?ReleaseID=352313
- 39 Heimes B, Lommatzsch A, Zeimer M. et al . Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol. 2008; 246 1229-1234
- 40 Macular Photocoagulation Study Group . Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991; 109 1109-1114
- 41 Colquitt J L, Jones J, Tan S C. et al . Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008; 12 iii-iv, ix-201
- 42 NICE technology appraisal guidance 155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. 2008; , www.nice.org.uk/TA155
- 43 Schmidt-Erfurth U M, Richard G, Augustin A. et al . Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007; 85 486-494
- 44 Empfehlung der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands für die Durchführung von intravitrealen Injektionen (IVI). 2007; , http://www.dog.org/publikationen/DOG_Empfehlung_Intravitreale_Injektionen.pdf
- 45 Aiello L P, Brucker A J, Chang S. et al . Evolving guidelines for intravitreous injections. Retina. 2004; 24 S3-19
- 46 Scott I U, Flynn H W. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007; 27 10-12
- 47 Meyer C H, Mennel Jr S, Eter N. Endophthalmitisrate mit und ohne topische postoperative Antibiotikagabe nach intravitrealer Avastin-injektion. Ophthalmologe. 2007; 104 952-957
- 48 Hart D. Off-Label-Use von Arzneimitteln: Hintergründe und Lösungsansätze eines vielschichtigen Problems. Arzneimittelbrief. 2008; 42 81-96
- 49 Dierks C, Nitz G. Rechtsfortbildung dank Lucentis?. Gesellschaftspolitische Kommentare. 2008; 11 3-7
- 50 Hart D. Arzthaftung und off label use. Information, Standard und Zulassung. Medizinrecht heute: Erfahrungen, Analysen, Entwicklungen Festschrift: 10 Jahre Arbeitsgemeinschaft Medizinrecht im DAW Deutscher Anwaltverlag 2008: 173-190
- 51 Francke R, Hart D. Off label use – Arzneimittelrechtliche, haftungsrechtliche, berufsrechtliche und sozialrechtliche Fragen. Die Sozialgerichtsbarkeit. 2003; 50 653-664